Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord DrugsBOM:538965 +0.66%67 Days Inventory is 68.24 as of Mar. 2026, which is 52% below its 10-year median of 143.45. GuruFocus rates BOM:538965 with a GF Score™ of 67/100 and a GF Value™ of ₹60.96 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Concord Drugs ranks better than 61.39% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Concord Drugs's Average Total Inventories for the
three
months ended in Mar. 2026 was ₹255.2 Mil. Concord Drugs's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹341.2 Mil.
Hence, Concord Drugs's Days Inventory for the
three
months ended in Mar. 2026 was 68.24.
The historical rank and industry rank for Concord Drugs's Days Inventory or its related term are showing as below:
BOM:538965'
s Days Inventory Range Over the Past 10 Years
Min: 75.68 Med: 143.45 Max: 249.64
Current: 137.52
During the past 13 years, Concord Drugs's highest Days Inventory was 249.64. The lowest was 75.68. And the median was 143.45.
BOM:538965's Days Inventory is ranked better than 61.39% of 922
companies
in the Drug Manufacturers industry
Industry Median: 165.005
vs BOM:538965: 137.52
Concord Drugs's Days Inventory
declined
from Mar. 2025 (291.64) to Mar. 2026 (68.24).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Concord Drugs's Inventory Turnover for the
three
months ended in Mar. 2026 was 1.34.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Concord Drugs's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.67.
Concord Drugs (BOM:538965) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Concord Drugs's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Concord Drugs's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Concord Drugs Days Inventory Related Terms
Concord Drugs Days Inventory Historical Data
* Premium members only.
The historical data trend for Concord Drugs's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Drugs Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Days Inventory distribution charts can be found below:
* The bar in red indicates where Concord Drugs's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Drugs (BOM:538965) has a Days Inventory of 68.24 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Concord Drugs and its competitors. This is 52% below median its historical median of 143.45. Over the past decade, Concord Drugs' Days Inventory has ranged from 75.68 to 249.64. According to the industry distribution chart, Concord Drugs ranks #356 out of 922 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Concord Drugs' Days Inventory too high?
Concord Drugs' current Days Inventory of 68.24 is 52% below median its 10-year median of 143.45. Over the past 10 years, this metric has ranged from a low of 75.68 to a high of 249.64. The Drug Manufacturers industry median Days Inventory is 165.01. Concord Drugs' value of 68.24 is 58.6% below this industry median. Based on the distribution chart, Concord Drugs ranks #356 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Concord Drugs has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Concord Drugs ranks #356 out of 922 companies for Days Inventory. This puts Concord Drugs in the upper half of its industry. The industry median Days Inventory is 165.01. Concord Drugs' value of 68.24 is 58.6% below this benchmark. Historically, Concord Drugs' own Days Inventory has ranged from 75.68 to 249.64 over the past decade. While the company's 10-year median is 143.45 vs. the industry median of 165.01, Concord Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 165.01, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Drugs's current Days Inventory of 68.24 is 58.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Concord Drugs and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 165.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Drugs's current Days Inventory is 68.24, which is 52% below median its own 10-year median of 143.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹60.96, compared to a current price of ₹71.70 — trading 17.6% above its estimated fair value. The current Days Inventory is 68.24, which is 52% below median its 10-year median of 143.45 and 58.6% below the Drug Manufacturers industry median of 165.01. Concord Drugs' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Days Inventory is 68.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Drugs (BOM:538965) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued.
The current stock price of ₹71.70 is trading 17.6% above its estimated GF Value™ of ₹60.96.
GuruFocus considers Concord Drugs to be Modestly Overvalued.
Key valuation signals for BOM:538965:
Days Inventory: 68.24 (52% below median its 10-year median of 143.45)
GF Value™: ₹60.96 vs. price of ₹71.70 (17.6% above fair value)
Industry Position: 58.6% below the Drug Manufacturers median (#356 of 922)
No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
67GF Score
Get the complete analysis for BOM:538965
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538965 has been successfully added to your 
